|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cao W, Chen HD, Yu YW, Li N and Chen WQ:
Changing profiles of cancer burden worldwide and in China: A
secondary analysis of the global cancer statistics 2020. Chin Med J
(Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leprince D, Gegonne A, Coll J, de Taisne
C, Schneeberger A, Lagrou C and Stehelin D: A putative second
cell-derived oncogene of the avian leukaemia retrovirus E26.
Nature. 306:395–397. 1983. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nunn MF, Seeburg PH, Moscovici C and
Duesberg PH: Tripartite structure of the avian erythroblastosis
virus E26 transforming gene. Nature. 306:391–395. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sperone A, Dryden NH, Birdsey GM, Madden
L, Johns M, Evans PC, Mason JC, Haskard DO, Boyle JJ, Paleolog EM
and Randi AM: The transcription factor Erg inhibits vascular
inflammation by repressing NF-kappaB activation and proinflammatory
gene expression in endothelial cells. Arterioscler Thromb Vasc
Biol. 31:142–150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yuan L, Le Bras A, Sacharidou A, Itagaki
K, Zhan Y, Kondo M, Carman CV, Davis GE, Aird WC and Oettgen P:
ETS-related gene (ERG) controls endothelial cell permeability
via transcriptional regulation of the claudin 5 (CLDN5)
gene. J Biol Chem. 287:6582–6591. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Birdsey GM, Dryden NH, Amsellem V,
Gebhardt F, Sahnan K, Haskard DO, Dejana E, Mason JC and Randi AM:
Transcription factor Erg regulates angiogenesis and endothelial
apoptosis through VE-cadherin. Blood. 111:3498–3506. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vijayaraj P, Le Bras A, Mitchell N, Kondo
M, Juliao S, Wasserman M, Beeler D, Spokes K, Aird WC, Baldwin HS
and Oettgen P: Erg is a crucial regulator of
endocardial-mesenchymal transformation during cardiac valve
morphogenesis. Development. 139:3973–3985. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tomlins SA, Rhodes DR, Perner S,
Dhannasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J,
Kuefer R, et al: Recurrent fusion of TMPRSS2 and ETS transcription
factor genes in prostate cancer. Science. 310:644–648. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sedarsky J, Degon M, Srivastava S and Dobi
A: Ethnicity and ERG frequency in prostate cancer. Nat Rev Urol.
15:125–131. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Salagierski M and Schalken JA: PCA3 and
TMPRSS2-ERG: Promising biomarkers in prostate cancer diagnosis.
Cancers (Basel). 2:1432–1440. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saramäki OR, Harjula AE, Martikainen PM,
Vessella RL, Tammela TL and Visakorpi T: TMPRSS2:ERG fusion
identifies a subgroup of prostate cancers with a favorable
prognosis. Clin Cancer Res. 14:3395–3400. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brady L, Carlsson J, Baird AM, Casey O,
Vlajnic T, Murchan P, Cormican D, Costigan D, Gray S, Sheils O, et
al: Correlation of integrated ERG/PTEN assessment with biochemical
recurrence in prostate cancer. Cancer Treat Res Commun.
29:1004512021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berg KD, Vainer B, Thomsen FB, Røder MA,
Gerds TA, Toft BG, Brasso K and Iversen P: ERG protein expression
in diagnostic specimens is associated with increased risk of
progression during active surveillance for prostate cancer. Eur
Urol. 66:851–860. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kong DP, Chen R, Zhang CL, Zhang W, Xiao
GA, Wang FB, Ta N, Gao X and Sun YH: Prevalence and clinical
application of TMPRSS2-ERG fusion in Asian prostate cancer
patients: A large-sample study in Chinese people and a systematic
review. Asian J Androl. 22:200–207. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Humphrey PA, Moch H, Cubilla AL, Ulbright
TM and Reuter VE: The 2016 WHO classification of tumours of the
urinary system and male genital organs-part B: Prostate and bladder
tumours. Eur Urol. 70:106–119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Paner GP, Stadler WM, Hansel DE, Montironi
R, Lin DW and Amin MB: Updates in the Eighth Edition of the
tumor-node-metastasis staging classification for urologic cancers.
Eur Urol. 73:560–569. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gębska E, Sikora-Żydek A, Michalski M,
Reichman-Warmusz E, Kurek J, Dudek D, Skowron W, Jarząb J and
Wojnicz R: Tissue hemostasis is shifted toward thrombogenesis in
the psoriatic plaques. Pathol Res Pract. 213:1125–1129. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Perner S, Mosquera JM, Demichelis F, Hofer
MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De
Marzo AM and Rubin MA: TMPRSS2-ERG fusion prostate cancer: An early
molecular event associated with invasion. Am J Surg Pathol.
31:882–888. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen Y, Chi P, Rockowitz S, Iaquinta PJ,
Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J, et al:
ETS factors reprogram the androgen receptor cistrome and prime
prostate tumorigenesis in response to PTEN loss. Nat Med.
19:1023–1029. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Z, Wang Y, Zhang J, Hu Q, Zhi F,
Zhang S, Mao D, Zhang Y and Liang H: Significance of the
TMPRSS2:ERG gene fusion in prostate cancer. Mol Med Rep.
16:5450–5458. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei Y, Peng J, He S, Huang H, Lin L, Zhu
Q, Ye L, Li T, Zhang X, Gao Y and Zheng X: miR-223-5p targeting ERG
inhibits prostate cancer cell proliferation and migration. J
Cancer. 11:4453–4463. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shah RB: Clinical applications of novel
ERG immunohistochemistry in prostate cancer diagnosis and
management. Adv Anat Pathol. 20:117–124. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland
SJ, Zheng Y and Ye D: Epidemiology and genomics of prostate cancer
in Asian men. Nat Rev Urol. 18:282–301. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bastus NC, Boyd LK, Mao X, Stankiewicz E,
Kudahetti SC, Oliver RT, Berney DM and Lu YJ: Androgen-induced
TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells.
Cancer Res. 70:9544–9548. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nguyen PN, Violette P, Chan S, Tanguay S,
Kassouf W, Aprikian A and Chen JZ: A panel of TMPRSS2:ERG fusion
transcript markers for urine-based prostate cancer detection with
high specificity and sensitivity. Eur Urol. 59:407–414. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin DW, Newcomb LF, Brown EC, Brooks JD,
Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, et
al: Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort:
Results from a baseline analysis in the canary Prostate Active
Surveillance Study. Clin Cancer Res. 19:2442–2450. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park K, Dalton JT, Narayanan R, Barbieri
CE, Hancock ML, Bostwick DG, Steiner MS and Rubin MA: TMPRSS2:ERG
gene fusion predicts subsequent detection of prostate cancer in
patients with high-grade prostatic intraepithelial neoplasia. J
Clin Oncol. 32:206–211. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sisodiya SM: Precision medicine and
therapies of the future. Epilepsia. 62 (Suppl 2):S90–S105. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Loibl S, Poortmans P, Morrow M, Denkert C
and Curigliano G: Breast cancer. Lancet. 397:1750–1769. 2021.
View Article : Google Scholar : PubMed/NCBI
|
